» Articles » PMID: 37684066

Selection and Prejudice: Addressing Clinical Trial Disparities With a Review of Current Shortcomings and Future Directions

Overview
Specialties Oncology
Radiology
Date 2023 Sep 8
PMID 37684066
Authors
Affiliations
Soon will be listed here.
Abstract

Growing evidence has demonstrated significant, persistent, and widespread disparities in cancer clinical trial enrollment across myriad disease sites and target populations. Although mechanisms underlying such disparities are complex and multifactorial, clinical trial eligibility criteria may serve as a key structural barrier to equitable and diverse trial enrollment. In this review, we provide an overview of the data describing historical and current disparities in cancer clinical trial enrollment and subsequently describe several patient-, institution-, and trial-related factors which appear to be key drivers of enrollment inequity, with specific discussion regarding the impact of eligibility criteria. We further describe the landscape of ongoing professional efforts aimed at eliminating clinical trial disparities through various medical, professional, and advocacy groups. The review concludes with a practical discussion of how modernization of eligibility criteria in clinical trials may decrease or eliminate trial disparities, including specific actionable recommendations aimed at improving the quality of future eligibility criteria.

Citing Articles

Clinical insights: five-year follow-up of KEYNOTE-189 trial outcomes and more.

Se B, Eysa A, Karim N Transl Lung Cancer Res. 2024; 13(8):2095-2097.

PMID: 39263022 PMC: 11384474. DOI: 10.21037/tlcr-24-198.

References
1.
Nipp R, Hong K, Paskett E . Overcoming Barriers to Clinical Trial Enrollment. Am Soc Clin Oncol Educ Book. 2019; 39:105-114. DOI: 10.1200/EDBK_243729. View

2.
Bumanlag I, Abi Jaoude J, Rooney M, Taniguchi C, Ludmir E . Exclusion of Older Adults from Cancer Clinical Trials: Review of the Literature and Future Recommendations. Semin Radiat Oncol. 2022; 32(2):125-134. PMC: 8944215. DOI: 10.1016/j.semradonc.2021.11.003. View

3.
Kim E, Uldrick T, Schenkel C, Bruinooge S, Harvey R, Magnuson A . Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clin Cancer Res. 2021; 27(9):2394-2399. DOI: 10.1158/1078-0432.CCR-20-3852. View

4.
Briel M, Elger B, McLennan S, Schandelmaier S, von Elm E, Satalkar P . Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada. Trials. 2021; 22(1):844. PMC: 8613940. DOI: 10.1186/s13063-021-05818-0. View

5.
Eskander M, Gil L, Beal E, Li Y, Hamad A, Oppong B . Access Denied: Inequities in Clinical Trial Enrollment for Pancreatic Cancer. Ann Surg Oncol. 2021; 29(2):1271-1277. DOI: 10.1245/s10434-021-10868-4. View